Tonix Pharmaceuticals Holding Corp. (TNXP): EBITDA
-$123.80M
Year ended 2025-12-31
-$163.32M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$123.80M | n/m | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | -$133.80M | n/m | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | -$114.58M | n/m | 2025-03-18, From 2023-01-01 |
| 2022-12-31 | -$110.79M | n/c | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | -$92.26M | n/m | 2023-03-13, From 2021-01-01 |
| 2020-12-31 | -$50.48M | n/m | 2022-03-14, From 2020-01-01 |
| 2019-12-31 | -$28.80M | n/m | 2021-03-15, From 2019-01-01 |
| 2018-12-31 | -$26.27M | n/m | 2020-03-24, From 2018-01-01 |
| 2017-12-31 | -$21.23M | n/a | 2019-03-18, From 2017-01-01 |
| No annual figure between 2015-12-31 and 2017-12-31. | |||
| 2015-12-31 | -$48.07M | n/m | 2017-04-13, From 2015-01-01 |
| 2014-12-31 | -$27.62M | n/m | 2016-03-03, From 2014-01-01 |
| 2013-12-31 | -$10.87M | n/a | 2016-03-03, From 2013-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | -$123.80M | n/m |
| Evommune, Inc. (EVMN) | 2025-12-31 | -$80.47M | n/m |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | -$278.0K | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $270.0K | n/m |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | -$79.91M | n/m |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | -$102.86M | n/m |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | -$43.99M | n/m |
| uniQure N.V. (QURE) | 2025-12-31 | -$170.59M | n/m |
| Precigen, Inc. (PGEN) | 2025-12-31 | -$107.31M | n/m |
Compare TNXP, EVMN, CVSI, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗